Olajossy Marcin, Olajossy Bartosz, Wnuk Sebastian, Potembska Emilia, Urbańska Ewa
II Klinika Psychiatrii i Rehabilitacji Psychiatrycznej Uniwersytetu Medycznego w Lublinie.
Katedra i Zakład Farmakologii Doświadczalnej i Klinicznej, Pracownia Farmakologii Komórkowej i Molekularnej.
Psychiatr Pol. 2017 Jun 18;51(3):455-468. doi: 10.12740/PP/61584.
The aim of the present study was to compare blood serum kynurenic acid (KYNA) concentrations measured before ECT and after 1, 6 and 12 electroconvulsive treatment (ECT) sessions in patients with diagnoses of recurrent depressive disorder (RDD), depression in bipolar disorder (DBD) and schizoaffective disorder (SAD).
The study group comprised of 50 patients with ICD-10 diagnoses of RDD, DBD and SAD. Blood serum KYNA concentrations were determined and clinical assessment was performed using the MADRS and the GAF scale.
Significant differences were found in blood serum KYNA levels between RDD, DBD and SAD patients treated with electroconvulsive therapy and healthy controls: 1) KYNA concentrations in DBD patients measured before ECT and after 12 ECT sessions were significantly lower than in the control group; 2) KYNA concentrations in the serum of RDD patients measured before ECT and after one and 12 ECT sessions were significantly lower than in the control group, while those measured after 6 ECT session did not differ significantly from KYNA concentrations in healthy controls; 3) higher pre-treatment blood serum concentrations of KYNA in DBD patients correlated with a higher number of illness phases and poorer general functioning before treatment; 4) significant relationships were found between higher blood serum concentrations of KYNA in RDD patients after 1 ECT session and male gender, and between higher KYNA concentrations after 6 ECT sessions and increased depression and poorer functioning before treatment in those patients.
Results show that KYNA concentrations in all diagnostic groups were lower before ECT (not statistically significant for the SAD group) and that there were no significant changes in those concentrations (compared with the baseline) during ECT.
本研究旨在比较诊断为复发性抑郁症(RDD)、双相情感障碍抑郁症(DBD)和分裂情感性障碍(SAD)的患者在接受电休克治疗(ECT)前以及1次、6次和12次ECT治疗后的血清犬尿喹啉酸(KYNA)浓度。
研究组由50例根据国际疾病分类第10版(ICD - 10)诊断为RDD、DBD和SAD的患者组成。测定血清KYNA浓度,并使用蒙哥马利 - 阿斯伯格抑郁量表(MADRS)和大体功能评定量表(GAF)进行临床评估。
接受电休克治疗的RDD、DBD和SAD患者与健康对照组之间血清KYNA水平存在显著差异:1)DBD患者在ECT治疗前和12次ECT治疗后的KYNA浓度显著低于对照组;2)RDD患者在ECT治疗前、1次和12次ECT治疗后的血清KYNA浓度显著低于对照组,而在6次ECT治疗后的血清KYNA浓度与健康对照组无显著差异;3)DBD患者治疗前血清KYNA浓度较高与疾病发作次数较多及治疗前总体功能较差相关;4)RDD患者在1次ECT治疗后血清KYNA浓度较高与男性性别相关,在6次ECT治疗后血清KYNA浓度较高与这些患者治疗前抑郁加重及功能较差相关。
结果表明,所有诊断组在ECT治疗前KYNA浓度均较低(SAD组无统计学意义),且在ECT治疗期间这些浓度与基线相比无显著变化。